---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-004106"
form_type: "8-K"
ticker: "RLAY"
cik: "0001812364"
company_name: "Relay Therapeutics, Inc."
filed_at: "2023-02-23T23:59:59+00:00"
generated_at: "2026-06-19T03:14:00.602697+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Relay Therapeutics reports Q4 2022 net loss of $67.5M; cash ~$1B funds into 2025

## Summary
- Net loss per share $0.56 for Q4 2022, flat vs Q4 2021; full-year net loss $290.5M ($2.59/share).
- Cash, cash equivalents and investments ~$1.0B as of Dec 31, 2022, up from $958.1M year-end 2021.
- RLY-4008 interim data: 88% ORR at pivotal dose (70 mg) in FGFR2-fusion cholangiocarcinoma; registrational path set.
- Breast cancer portfolio: RLY-2608 monotherapy and combination arms ongoing; initial data expected H1 2023.
- Raised $300M gross proceeds in follow-on public offering; R&D expenses $246.4M for full year 2022.

## SEC filing metadata
- accession: 0000950170-23-004106
- form_type: 8-K
- ticker: RLAY
- cik: 0001812364
- company_name: Relay Therapeutics, Inc.
- filed_at: 2023-02-23T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1812364/000095017023004106/0000950170-23-004106-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1812364/000095017023004106/rlay-20230223.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-004106
- JSON: https://secwatch.observer/filing/0000950170-23-004106.json
- Plain text: https://secwatch.observer/filing/0000950170-23-004106.txt

## Key facts
- Earnings Releases
  Relay Therapeutics, Inc. reported the fourth quarter of 2022 results: net income $67.5 million, EPS $0.56.
  - Period: the fourth quarter of 2022
  - Net income: $67.5 million
  - EPS: $0.56
  - Result: reported results
  source text: Net loss was $67.5 million for the fourth quarter of 2022, or a net loss per share of $0.56
  evidence_url: https://www.sec.gov/Archives/edgar/data/1812364/000095017023004106/0000950170-23-004106-index.htm
- Earnings Releases
  Relay Therapeutics, Inc. reported financial results for the full year 2022.
  - Period: the full year 2022
  - Result: reported results
  source text: On February 23, 2023, Relay Therapeutics, Inc. announced its financial results for the quarter and year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1812364/000095017023004106/0000950170-23-004106-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.